Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
Yoshiaki NakamuraWataru OkamotoTadamichi DendaTomohiro NishinaYoshito KomatsuSatoshi YukiHisateru YasuiTaito EsakiYu SunakawaMakoto UenoEiji ShinozakiNobuhisa MatsuhashiTakashi OhtaKen KatoKoushiro OhtsuboHideaki BandoHiroki HaraTaroh SatohKentaro YamazakiYoshiyuki YamamotoNaohiro OkanoTetsuji TerazawaTakeshi KatoEiji OkiAkihito TsujiYosuke HoritaYasuo HamamotoAkihito KawazoeHiromichi NakajimaShogo NomuraRyuta MitaniMihoko YuasaKiwamu AkagiTakayuki YoshinoPublished in: JCO precision oncology (2022)
ctDNA genotyping was able to detect MSI with high concordance to validated tissue-based MSI testing, especially in patients with tumors that have sufficient ctDNA shedding. Furthermore, ctDNA genotyping enabled identification of patients with MSI-H tumors who benefited from immune checkpoint inhibitor treatment.